Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism

The DNA methyltransferase inhibitor decitabine has classically been used to reactivate silenced genes and as a pretreatment for anticancer therapies. In a variation of this idea, this study explores the concept of adding low-dose decitabine (DAC) following administration of chemotherapy to bolster t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez, Wade R., Scherer, Amanda, Rytlewski, Jeffrey D., Laverty, Emily A., Sheehan, Alexa P., McGivney, Gavin R., Brockman, Qierra R., Knepper-Adrian, Vickie, Roughton, Grace A., Quelle, Dawn E., Gordon, David J., Monga, Varun, Dodd, Rebecca D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746804/
https://www.ncbi.nlm.nih.gov/pubmed/36227698
http://dx.doi.org/10.1172/jci.insight.159419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746804/
https://www.ncbi.nlm.nih.gov/pubmed/36227698
http://dx.doi.org/10.1172/jci.insight.159419

Ejemplares similares